Neil Osheroff

Crucial research by Neil Osheroff and his lab led to FDA approval of the first new class of antibacterial drugs in decades. The drug, gepotidacin, developed by GlaxoSmithKline under the brand name Blujepa, is now approved to treat uncomplicated urinary tract infections and gonorrhea. Read More

Led by Neil Osheroff, Vanderbilt researchers are the first to undertake a systematic analysis of the mechanism of action of gepotidacin, a first-in-class triazaacenaphthylene antibacterial, against its targets in Escherichia coli—the type II topoisomerases gyrase and topoisomerase IV—and the mechanistic basis for drug resistance. E. coli is the etiological agent of most urinary tract infections. Read More

As a professor of biochemistry and medicine at Vanderbilt University School of Medicine for more than 40 years, Osheroff is the longest serving course director currently teaching medical students. He also codirects the preclerkship phase of the medical school curriculum and leads the Master Science Teachers cohort, a role established in 2007 to recognize VUSM’s outstanding basic science educators. Through his teaching, he has helped medical students at VUSM and across the globe acquire the basic science skills and knowledge they need to thrive in clinical practice, according to the AAMC. Read More

Vanderbilt's James E. Crowe, Jr, MD, and Neil Osheroff, PhD, are among 12 individuals honored by the Association of American Medical Colleges during its 2023 Awards Recognition Event. Read More

Neil Osheroff received the Mentoring, Innovation, and Leadership in Educational Scholarship Award at the annual Asia Pacific Medical Education Conference that took place in May. Read More

New research into the enzyme topoisomerase II sheds light on how it helps DNA replicate properly. Read More

Vanderbilt researchers describe how certain tuberculosis treatments work and suggest these medications may overcome the threat of drug-resistant tuberculosis. Read More

It’s not often that a keynote speaker will ask his audience to close their eyes and tune him out, but that’s what Aviad “Adi” Haramati, PhD, did when delivering the 2018 John E. Chapman Lecture. Read More

New mechanistic details about the DNA-unwinding activity of antibacterial protein targets could lead to the design of better antibiotic medicines. Read More

Vanderbilt University School of Medicine (VUSM) recently established the Academy for Excellence in Education Lillian B. Nanney Award for Outstanding Service to the VUSM/Vanderbilt University Medical Center (VUMC) Community of Educators. Read More

Neil Osheroff, Ph.D., has been named director of the Academy for Excellence in Education. He succeeds Lillian Nanney, Ph.D., who served as director since the Academy’s inception in 2007. Read More

One small chemical change to an existing antibacterial drug results in a compound that is more effective against its target enzyme in tuberculosis, Vanderbilt researchers have discovered. Read More

Compounds found in olives and olive oil have anticancer activity, which may contribute to the cancer preventive properties attributed to the Mediterranean diet. Read More

A series of experimental antibiotics may be a good starting point for developing new anticancer drugs. Read More

Understanding how bacteria become resistant to quinolone antibiotics could guide strategies for developing new antibacterial drugs. Read More

New details on the DNA-cutting activity of topoisomerase II, a target of anti-cancer drugs, could lead to better chemotherapeutic agents. Read More